Drug Trial Radar · NCT05772520
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Jan 19, 2023
Primary completion
Dec 1, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- Hangzhou Highlightll Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 2 doses of TLL018 as therapy in approximately 90 participants with moderate-to-severe PP.
Conditions
- Plaque Psoriasis
Interventions
TLL018 tabletsDrug
oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving PASI-75 (FAS)Time frame: Week12
- Proportion of Participants Achieving PASI 75 (PPS)Time frame: Week12
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Cahaba
Birmingham, Alabama
Moy, Fincher, Chipps
Beverly Hills, California
Metropolis Derm
Los Angeles, California
Amicis Research Center
Northridge, California
Integrative Skin
Sacramento, California
Skin Surgical
San Diego, California
Life Clinical Trials
Coral Springs, Florida
Palm Beach
DeLand, Florida
D&H Doral Research Center LLC
Doral, Florida
Sweet Hope Research Specialty, Inc
Hialeah, Florida
CNS - Jacksonville
Jacksonville, Florida
CNS - Orlando SODO
Jacksonville, Florida
Altus Research
Lake Worth, Florida
Anchor Medical Research, LLC (Core Clinical Trials)
Miami, Florida
Reserka Research
Miami, Florida
ForCare Medical (CenExcel)
Tampa, Florida
Integrated Clinical Trial Services, Inc
Des Moines, Iowa
IMA Clinical Research
Monroe, Louisiana
Lawrence Green
Rockville, Maryland
Metro Boston
Brighton, Massachusetts
Oakland Hills Dermatology
Auburn Hills, Michigan
Revival Research Institute
Troy, Michigan
Grekin Skin
Warren, Michigan
Minnesota Clinical Study Center
New Ulm, Minnesota
Mount Sinai
New York, New York
Sadick Research Group
New York, New York
Remington-Davis, Inc.
Columbus, Ohio
DermDox
Sugarloaf, Pennsylvania
CRCC
Charleston, South Carolina
Dermatology Associates of Knoxville
Knoxville, Tennessee
Derm Research
Austin, Texas
Studies in Dermatology, LLC
Cypress, Texas
Austin Institute for Clinical Research
Pflugerville, Texas
Progressive Clinical Research Group, Inc.
San Antonio, Texas
Acclaim
Sugar Land, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.